Clinical and radiologic evaluation of cytomegalovirus-induced thrombocytopenia in infants between 1 and 6 months of age.
- Author:
Joon Won KANG
1
;
Gee Na KIM
;
Sun Young KIM
;
Hee Jin KIM
;
Eun Sil PARK
;
Jae Young KIM
;
Young Ho LEE
Author Information
- Publication Type:Original Article
- Keywords: Thrombocytopenia; Cytomegalovirus; Infant
- MeSH: Aged; Brain; Cytomegalovirus; Follow-Up Studies; Hearing; Humans; Immunoglobulin G; Immunoglobulin M; Infant; Infant, Newborn; Magnetic Resonance Imaging; Platelet Count; Polymerase Chain Reaction; Thrombocytopenia
- From:Korean Journal of Hematology 2010;45(1):29-35
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Up to 90% of neonates with congenital or perinatal cytomegalovirus (CMV) infection are asymptomatic, and little is known about CMV-associated thrombocytopenia after the neonatal period. We investigated the clinical findings of a series of infants diagnosed with CMV infection and thrombocytopenia. METHODS: From July 2005 to July 2008, infants aged younger than 6 months with thrombocytopenia were screened for CMV infection, using CMV IgM. Those who were positive for CMV IgM were then tested for CMV IgG via polymerase chain reaction (PCR) for CMV and CMV pp65 Ag and urine culture. Brain magnetic resonance imaging (MRI) and otologic and ophthalmologic evaluations were also performed. RESULTS: Twenty-one patients aged between 1 and 6 months (11 boys and 10 girls) were admitted and tested for CMV infection. Six patients (28.6%) were positive for CMV IgM; these were also positive for CMV IgG, CMV PCR, and urine culture, and 4 were also positive for CMV pp65 Ag. The median platelet count at admission was 6,500/microliter (range, 2,000-105,000/microliter). One patient (16.7%) was diagnosed with Evans syndrome and had calcifications on brain MRI. One patient had unilateral sensorineural hearing loss. CONCLUSION: Thrombocytopenia can be the main clinical manifestation of otherwise asymptomatic CMV infection after the neonatal period, and close follow-up of neurodevelopmental sequelae is needed.
